Drew R Oostra1, Maryam B Lustberg2, Raquel E Reinbolt3, Xueliang Pan4, Robert Wesolowski3, Charles L Shapiro3. 1. The Ohio State University Wexner Medical Center, Columbus, OH, USA. 2. The Breast Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; Stefanie Spielman Comprehensive Breast Center, Columbus, OH, USA. Electronic address: Maryam.lustberg@osumc.edu. 3. The Breast Program, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; Stefanie Spielman Comprehensive Breast Center, Columbus, OH, USA. 4. Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
Abstract
PURPOSE: Chemotherapy induced ovarian failure (CIOF) results in rapid bone loss. Receptor Activator of Nuclear Factor Kappa-B (RANK)-RANK ligand (RANK-L) signaling balances bone resorption and formation. Osteoprotegerin (OPG) acts as a decoy receptor for RANK, interrupting osteoclast activation and bone resorption. This study examined the relationship between OPG and bone loss in women with CIOF. METHODS: Premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated at chemotherapy initiation, 6 and 12 months. Bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN), follicle stimulating hormone (FSH), ionized calcium, osteocalcin, and OPG were serially measured. CIOF was defined as a negative pregnancy test, FSH levels >30 MIU/mL, and ≥3 months of amenorrhea. RESULTS: Forty women were enrolled; 31 (77.5%) met CIOF criteria. BMD significantly decreased (p < 0.001) in the CIOF group at both time points: LS BMD decreased from a median of 0.993 g/cm(2) to 0.976 g/cm(2) and 0.937 g/cm(2) at 6 and 12 months, respectively. OPG was significantly elevated at 6 months (median increase 0.30 pmol/L, p = 0.015) and then decreased at 12 months to levels still above baseline (median difference 0.2 pmol/L, p = 0.70). CONCLUSIONS: In what was likely a compensatory response to rapid bone loss, CIOF patients' OPG levels increased at 6 months and then decreased at 12 months to values greater than baseline assessments. This phenomenon is described in other diseases, but never before in CIOF.
PURPOSE: Chemotherapy induced ovarian failure (CIOF) results in rapid bone loss. Receptor Activator of Nuclear Factor Kappa-B (RANK)-RANK ligand (RANK-L) signaling balances bone resorption and formation. Osteoprotegerin (OPG) acts as a decoy receptor for RANK, interrupting osteoclast activation and bone resorption. This study examined the relationship between OPG and bone loss in women with CIOF. METHODS: Premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated at chemotherapy initiation, 6 and 12 months. Bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN), follicle stimulating hormone (FSH), ionizedcalcium, osteocalcin, and OPG were serially measured. CIOF was defined as a negative pregnancy test, FSH levels >30 MIU/mL, and ≥3 months of amenorrhea. RESULTS: Forty women were enrolled; 31 (77.5%) met CIOF criteria. BMD significantly decreased (p < 0.001) in the CIOF group at both time points: LS BMD decreased from a median of 0.993 g/cm(2) to 0.976 g/cm(2) and 0.937 g/cm(2) at 6 and 12 months, respectively. OPG was significantly elevated at 6 months (median increase 0.30 pmol/L, p = 0.015) and then decreased at 12 months to levels still above baseline (median difference 0.2 pmol/L, p = 0.70). CONCLUSIONS: In what was likely a compensatory response to rapid bone loss, CIOFpatients' OPG levels increased at 6 months and then decreased at 12 months to values greater than baseline assessments. This phenomenon is described in other diseases, but never before in CIOF.
Authors: C E Fiore; P Pennisi; G Ferro; B Ximenes; L Privitelli; R A Mangiafico; F Santoro; N Parisi; T Lombardo Journal: Horm Metab Res Date: 2006-06 Impact factor: 2.936
Authors: R J Stillman; J S Schinfeld; I Schiff; R D Gelber; J Greenberger; M Larson; N Jaffe; F P Li Journal: Am J Obstet Gynecol Date: 1981-01 Impact factor: 8.661
Authors: A Mizuno; N Amizuka; K Irie; A Murakami; N Fujise; T Kanno; Y Sato; N Nakagawa; H Yasuda; S Mochizuki; T Gomibuchi; K Yano; N Shima; N Washida; E Tsuda; T Morinaga; K Higashio; H Ozawa Journal: Biochem Biophys Res Commun Date: 1998-06-29 Impact factor: 3.575
Authors: I Fogelman; G M Blake; R Blamey; M Palmer; W Sauerbrei; M Schumacher; D Serin; A Stewart; W Wilpshaar Journal: Osteoporos Int Date: 2003-10-03 Impact factor: 4.507